Globeimmune Current Ratio 2013-2016 | GBIM
Globeimmune current ratio from 2013 to 2016. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Globeimmune Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2016-03-31 |
$0.01B |
$0.00B |
2.28 |
| 2015-12-31 |
$0.01B |
$0.00B |
2.63 |
| 2015-09-30 |
$0.01B |
$0.00B |
2.96 |
| 2015-06-30 |
$0.01B |
$0.01B |
2.76 |
| 2015-03-31 |
$0.02B |
$0.01B |
3.27 |
| 2014-12-31 |
$0.02B |
$0.01B |
3.44 |
| 2014-09-30 |
$0.02B |
$0.01B |
4.04 |
| 2014-06-30 |
$0.01B |
$0.02B |
0.48 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
|
0.00 |
| 2013-09-30 |
$0.00B |
|
0.00 |
| 2013-06-30 |
$0.00B |
|
0.00 |
| 2012-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
GlobeImmune, Inc. is a biopharmaceutical company. It is focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen (R) platform. The Company's products under development includes GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. GlobeImmune, Inc. is based in Louisville, Colorado.
|
